Skye Bioscience (SKYE) Divestments (2024 - 2025)
Skye Bioscience's (SKYE) quarterly Divestments came in at $179987.0 in Q4 2025, up 28.16% year-over-year from $140434.0 in Q4 2024, and up 96.92% quarter-over-quarter from $91400.0 in Q3 2025.
Powered by 
Analysis
Skye Bioscience (SKYE) Divestments (2024 - 2025) Analysis & Trends
Skye Bioscience (SKYE) has reported Divestments for 2 consecutive years, with $179987.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Divestments rose 28.16% year-over-year to $179987.0 in Q4 2025; TTM through Dec 2025 was $360750.0, a 73.44% decrease from a year earlier, with the FY2025 full-year figure at $360750.0, down 73.44% from the prior year.
- Divestments was $179987.0 for Q4 2025 at Skye Bioscience, up from $91400.0 in the prior quarter.
- Over five years, Divestments peaked at $1.1 million in Q1 2024 and troughed at $72837.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.71 Bn | 192.72 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.26 Bn | 177.08 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.29 Bn | 123.43 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.82 Bn | 73.83 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.94 Bn | 48.80 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.34 Bn | 30.03 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.87 Bn | 30.58 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.02 Bn | 29.02 Bn | 1.16 Mn | - |
| 10 | Skye Bioscience | 10.17 Mn | 10.17 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 179,987.00 |
| Sep 30, 2025 | 91,400.00 |
| Jun 30, 2025 | 89,363.00 |
| Dec 31, 2024 | 140,434.00 |
| Sep 30, 2024 | 72,837.00 |
| Mar 31, 2024 | 1.15 Mn |